Draximage takes skeletal imaging agent to the US:
This article was originally published in Clinica
Executive Summary
Draximage has launched in the US a new formulation of a skeletal imaging agent for pinpointing areas of altered osteogenesis or bone growth. MDP-25 (99mTc-methylene diphosphonic acid kit), when used with gamma camera imaging, allows doctors to detect areas of abnormal osteogenesis, which show altered uptake, making it possible to visualise a variety of bone lesions. It is used in the assessment of metastatic bone disease, Paget's disease, arthritic disease and osteomyelitis. The new formulation produces more effective images of the extremities of the skeleton, particularly hands and feet, claims the company, a subsidiary of Mississauga, Ontario-based Draxis Health.